Opus Genetics (IRD) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for ophthalmic disorders.

• Pipeline includes AAV-based gene therapies targeting genetically defined IRDs and a non-selective alpha-adrenergic antagonist for pupil size reduction.

• Lead programs address Leber congenital amaurosis (LCA5 gene) and retinal diseases linked to BEST1 gene mutations.

• Additional gene therapy programs in development for RDH12, MERTK, RHO, CNGB1, and NMNAT1, plus research on other monogenic retinal disorders.

Financial performance and metrics

• As of June 30, 2026, 82,647,946 shares of common stock were outstanding.

• Net tangible book value as of June 30, 2026, was approximately ($13.0) million or ($0.16) per share.

• After a $125 million offering at $3.64/share, as adjusted net tangible book value would be $108 million or $0.92/share.

• Immediate dilution to new investors estimated at $2.72 per share at the assumed offering price.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes and working capital, including preclinical studies, clinical trials, and advancement of product candidates.

• Management retains broad discretion over allocation and timing of expenditures.

• Pending use, proceeds will be invested in interest-bearing, investment-grade securities or government securities.